Skip to main content

Table 2 Histology-driven approach in soft tissue sarcomas

From: Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new

Histology

Cytotoxic compounds with selective activity

Target-therapies with selective activities

Leiomyosarcoma

Gemcitabine ± docetaxel, trabectedin, dacarbazine

Pazopanib

Dedifferentiated liposarcoma

High-dose ifosfamide, trabectedin, eribulin

 

Myxoid liposarcoma

Trabectedin, eribulin

 

Synovial sarcoma

Ifosfamide, trabectedin

Pazopanib

Epithelioid sarcoma

Gemcitabine

Pazopanib

Angiosarcoma/intimal sarcoma

Gemcitabine, paclitaxel

Pazopanib, sorafenib

Alveolar soft part sarcoma

 

Pazopanib, sunitinib, cedinarib

Solitary fibrous tumour

Dacarbazine

Pazopanib, sunitinib

Clear cell sarcoma

 

Pazopanib, sunitinib

Extraskeletal myxoid chondrosarcoma

 

Pazopanib, sunitinib

Perivascular epithelioid cell tumor

Gemcitabine

m-TOR inhibitors

Epithelioid hemangioendothelioma

 

Pazopanib, m-TOR inhibitors, interferon

Inflammatory myofibroblastic tumour

 

Crizotinib

Undifferentiated pleomorphic sarcoma

High-dose ifosfamide, gemcitabine

 

Dermatofibrosarcoma protuberans

 

Imatinib, sorafenib, sunitinib